NCT06799065View on ClinicalTrials.gov

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 21, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

August 30, 2027

Conditions
Advanced Solid TumorsBreast Cancer RecurrentOvarian CancerHigh-grade Serous Ovarian CarcinomaTriple Negative Breast Cancer
Interventions
DRUG

ATX-295

ATX-295 Tablets will be taken orally

Trial Locations (4)

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

SCRI Oncology Partners, Nashville

77030

RECRUITING

MD Anderson Cancer Center, Houston

78229

RECRUITING

NEXT Oncology, San Antonio

Sponsors
All Listed Sponsors
lead

Accent Therapeutics

INDUSTRY

NCT06799065 - First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Biotech Hunter | Biotech Hunter